Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Kyverna Therapeutics, Inc. received an updated ownership report showing that funds affiliated with Westlake BioPartners and Dr. Beth C. Seidenberg beneficially own a significant minority stake in the company’s common stock.
Westlake BioPartners Fund I, L.P. reports beneficial ownership of 3,787,940 shares of Kyverna common stock, representing 6.3% of the class. Westlake BioPartners Opportunity Fund I, L.P. reports 869,317 shares, or 1.5% of the class. In total, Dr. Seidenberg is reported as beneficially owning 4,657,257 shares, or 7.8% of Kyverna’s common stock as of the December 31, 2025 event date.
The filing explains that these shares are held through Westlake limited partnerships, with their respective general partners and Dr. Seidenberg “may be deemed” to have sole voting and dispositive power, while all reporting persons disclaim beneficial ownership beyond their pecuniary interest. The amendment also notes that Dr. Sean E. Harper is no longer a managing director of the general partners and is therefore removed as a reporting person.
Kyverna Therapeutics, Inc. reported a leadership transition and a change to its inducement equity plan. Karen Walker notified the company on January 29, 2026 that she will retire and step down as Chief Technology Officer, effective February 9, 2026. The company noted that her resignation is not due to any disagreement regarding operations, policies, or practices.
On the same date, the board’s Compensation Committee amended and restated the 2024 Inducement Equity Incentive Plan to increase the shares of common stock available for grant by 1,000,000, bringing the aggregate to 5,000,000 shares. This change was adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) and maintains the plan’s focus on equity awards used as material inducements for new or rehired employees. The company also announced the appointment of Mayo Pujols as Chief Technology Officer, effective February 9, 2026.
Kyverna Therapeutics Executive Chairperson Shaw Christi reported new equity awards from the company. On January 12, 2026, Shaw Christi received 30,000 shares of common stock as a restricted stock unit award, which vests in four equal annual installments starting January 12, 2027, subject to continued service.
She also received 24,301 performance restricted stock units that vest only if Kyverna’s common stock reaches specified share price targets. In addition, she was granted a stock option for 185,000 shares of common stock at an exercise price of $8.23 per share, with one quarter vesting on January 12, 2027 and the remainder vesting monthly thereafter, conditioned on continued service. Following these awards, she beneficially owned 70,935 shares of common stock and 185,000 stock options directly.
Kyverna Therapeutics appointed Christi Shaw as Executive Chairperson of its Board, effective January 12, 2026. She will replace Ian Clark as Chairperson, who will continue to serve as a director. Shaw will be employed on an at-will basis with an initial annual salary of $400,000.
As part of her compensation, Shaw will receive an option to purchase 185,000 shares of common stock and 30,000 restricted stock units, each vesting over four years, along with performance RSUs equal to $200,000 divided by the grant-date fair market value, which vest upon achieving specified stock price targets. If a change in control occurs during her employment, all of her unvested equity awards will fully vest, with performance targets deemed achieved at the target level.
The company also furnished a press release providing a corporate update, strategic priorities for 2026, and preliminary unaudited financial information for the year ended December 31, 2025, which may change upon completion of year-end procedures.
Kyverna Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 13,333,333 shares of common stock at a public offering price of $7.50 per share. Underwriters will purchase the shares at $7.05 per share and have a 30-day option to buy up to an additional 1,999,999 shares at the public offering price, less underwriting discounts and commissions.
The company expects gross proceeds of approximately $100 million, before deducting underwriting discounts, commissions and offering expenses. Kyverna intends to use the net proceeds for general corporate purposes, which may include funding research and development, capital expenditures, working capital and general and administrative expenses. Closing is expected on or about December 18, 2025, subject to customary conditions, and directors, executive officers and certain affiliated stockholders are subject to lock-up agreements generally through January 31, 2026.
Kyverna Therapeutics, Inc. is issuing 13,333,333 shares of common stock at $7.50 per share in a primary offering on the Nasdaq Global Select Market under the symbol KYTX. Underwriters have a 30-day option to buy up to an additional 1,999,999 shares at the same price, less underwriting discounts and commissions of $0.45 per share. Gross proceeds are approximately $99.999 million, with estimated net proceeds of about $93.7 million, or $107.8 million if the option is fully exercised.
The company plans to use the cash, together with existing cash and cash equivalents, prior at-the-market sales of $16.9 million and loan proceeds, for general corporate purposes including research and development, capital expenditures, working capital and administrative costs. Management believes this funding will support operations through 2028 and back a planned biologics license application for stiff person syndrome and a Phase 3 trial in generalized myasthenia gravis.
Kyverna is a clinical-stage cell therapy company focused on autoimmune diseases, led by its CD19 CAR T candidate mivocabtagene autoleucel (miv-cel). Recent registrational Phase 2 data in stiff person syndrome showed functional gains, sustained freedom from immunotherapies and no high-grade CRS or ICANS, with Grade 3/4 neutropenia reported in 62% of patients and described as manageable.
Kyverna Therapeutics' chief technology officer reported an option exercise and share sale in Kyverna Therapeutics, Inc. common stock. On 12/15/2025, the officer exercised stock options to acquire 23,998 shares at an exercise price of $4.83 per share and, on the same date, sold 23,998 shares at $12.2 per share. After these transactions, the officer beneficially owned 22,636 shares of common stock directly and held 85,865 stock options.
The filing states that these trades were made under a Rule 10b5-1 trading plan adopted on September 12, 2025, which automates transactions according to preset instructions. The option originally vested 25% of the shares on January 1, 2025, with the remaining portion vesting in equal monthly installments, contingent on continued service.
Kyverna Therapeutics is offering $100,000,000 of common stock, with underwriters holding a 30-day option to buy up to an additional $15.0 million of shares. The clinical-stage company develops CD19 CAR T-cell therapies for autoimmune diseases, led by its autologous candidate mivocabtagene autoleucel (miv-cel). It plans to use net proceeds, together with existing cash, for general corporate purposes including research and development, and states that, combined with prior at-the-market sales and loan proceeds, this financing is expected to fund operations through 2028 and support a planned BLA filing in stiff person syndrome (SPS) and a Phase 3 trial in myasthenia gravis (MG).
Kyverna recently reported positive topline data from the registrational KYSA-8 Phase 2 SPS trial in 26 patients: among 12 patients who needed a walking aid before treatment, 67% no longer required assistance at Week 16; 100% remained off immunotherapies without rescue therapy at last follow-up. Miv-cel was described as well-tolerated, with no high-grade CRS or ICANS and Grade 3/4 neutropenia in 62% of patients, which was reported as manageable and resolved.
Kyverna also highlights a non-dilutive term loan facility of up to $150.0 million with Oxford Finance. It has drawn $25.0 million, and the positive KYSA-8 data made an additional tranche of up to $20.0 million available, bringing currently available undrawn funding to $35.0 million. The company cautions that investing in its stock involves a high degree of risk, including dilution from this offering, potential future equity issuances, broad discretion over proceeds and significant stock price volatility.
Kyverna Therapeutics is offering $100,000,000 of common stock, with underwriters holding a 30-day option to buy up to an additional $15.0 million of shares. The clinical-stage company develops CD19 CAR T-cell therapies for autoimmune diseases, led by its autologous candidate mivocabtagene autoleucel (miv-cel). It plans to use net proceeds, together with existing cash, for general corporate purposes including research and development, and states that, combined with prior at-the-market sales and loan proceeds, this financing is expected to fund operations through 2028 and support a planned BLA filing in stiff person syndrome (SPS) and a Phase 3 trial in myasthenia gravis (MG).
Kyverna recently reported positive topline data from the registrational KYSA-8 Phase 2 SPS trial in 26 patients: among 12 patients who needed a walking aid before treatment, 67% no longer required assistance at Week 16; 100% remained off immunotherapies without rescue therapy at last follow-up. Miv-cel was described as well-tolerated, with no high-grade CRS or ICANS and Grade 3/4 neutropenia in 62% of patients, which was reported as manageable and resolved.
Kyverna also highlights a non-dilutive term loan facility of up to $150.0 million with Oxford Finance. It has drawn $25.0 million, and the positive KYSA-8 data made an additional tranche of up to $20.0 million available, bringing currently available undrawn funding to $35.0 million. The company cautions that investing in its stock involves a high degree of risk, including dilution from this offering, potential future equity issuances, broad discretion over proceeds and significant stock price volatility.
Kyverna Therapeutics, Inc. announced positive topline data from KYSA-8, a registrational Phase 2 trial of its fully human, autologous CD19 CAR T-cell therapy mivocabtagene autoleucel (miv-cel, formerly KYV-101) in stiff person syndrome.
The company is hosting a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results and has provided an investor slide presentation as Exhibit 99.1, which is furnished rather than filed under federal securities law provisions.
Kyverna Therapeutics, Inc. announced positive topline data from KYSA-8, a registrational Phase 2 trial of its fully human, autologous CD19 CAR T-cell therapy mivocabtagene autoleucel (miv-cel, formerly KYV-101) in stiff person syndrome.
The company is hosting a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results and has provided an investor slide presentation as Exhibit 99.1, which is furnished rather than filed under federal securities law provisions.
Kyverna Therapeutics reported positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome.
The company also stated it will host a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results, and made a detailed press release available describing the KYSA-8 data and its implications for the miv-cel program.
Kyverna Therapeutics reported positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome.
The company also stated it will host a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results, and made a detailed press release available describing the KYSA-8 data and its implications for the miv-cel program.